QGEN vs. TAK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at QGEN and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
QGEN is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | QGEN | TAK |
|---|---|---|
| Company Name | Qiagen N.V. | Takeda Pharmaceutical Company Limited |
| Country | Netherlands | Japan |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.67 billion USD | 49.02 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 28, 1996 | January 5, 2010 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of QGEN and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | QGEN | TAK |
|---|---|---|
| 5-Day Price Return | 0.49% | 2.30% |
| 13-Week Price Return | 14.95% | 10.63% |
| 26-Week Price Return | 22.82% | 9.73% |
| 52-Week Price Return | 4.79% | 5.51% |
| Month-to-Date Return | -0.28% | 9.26% |
| Year-to-Date Return | 10.49% | 9.76% |
| 10-Day Avg. Volume | 1.22M | 4.69M |
| 3-Month Avg. Volume | 1.45M | 4.19M |
| 3-Month Volatility | 21.16% | 14.84% |
| Beta | 0.68 | 0.36 |
Profitability
Return on Equity (TTM)
QGEN
10.66%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
QGEN’s Return on Equity of 10.66% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
TAK
1.48%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
TAK’s Return on Equity of 1.48% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
QGEN
18.30%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
A Net Profit Margin of 18.30% places QGEN in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
TAK
2.36%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 2.36% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
QGEN
22.84%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
An Operating Profit Margin of 22.84% places QGEN in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TAK
7.48%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
TAK’s Operating Profit Margin of 7.48% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | QGEN | TAK |
|---|---|---|
| Return on Equity (TTM) | 10.66% | 1.48% |
| Return on Assets (TTM) | 6.40% | 0.72% |
| Net Profit Margin (TTM) | 18.30% | 2.36% |
| Operating Profit Margin (TTM) | 22.84% | 7.48% |
| Gross Profit Margin (TTM) | 63.73% | 65.51% |
Financial Strength
Current Ratio (MRQ)
QGEN
1.61
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
QGEN’s Current Ratio of 1.61 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
TAK
1.01
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
TAK’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
QGEN
0.41
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
QGEN’s Debt-to-Equity Ratio of 0.41 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TAK
0.65
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
QGEN
27.84
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
QGEN’s Interest Coverage Ratio of 27.84 is in the upper quartile for the Life Sciences Tools & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
TAK
2.05
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 2.05 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | QGEN | TAK |
|---|---|---|
| Current Ratio (MRQ) | 1.61 | 1.01 |
| Quick Ratio (MRQ) | 1.19 | 0.52 |
| Debt-to-Equity Ratio (MRQ) | 0.41 | 0.65 |
| Interest Coverage Ratio (TTM) | 27.84 | 2.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
QGEN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TAK
4.23%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.23%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
QGEN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TAK
138.69%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 138.69% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | QGEN | TAK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.23% |
| Dividend Payout Ratio (TTM) | 0.00% | 138.69% |
Valuation
Price-to-Earnings Ratio (TTM)
QGEN
28.51
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
QGEN’s P/E Ratio of 28.51 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
TAK
66.26
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 66.26, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
QGEN
5.22
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
QGEN’s P/S Ratio of 5.22 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
TAK
1.56
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
TAK’s P/S Ratio of 1.56 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
QGEN
2.97
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
QGEN’s P/B Ratio of 2.97 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
TAK
1.01
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
TAK’s P/B Ratio of 1.01 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | QGEN | TAK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 28.51 | 66.26 |
| Price-to-Sales Ratio (TTM) | 5.22 | 1.56 |
| Price-to-Book Ratio (MRQ) | 2.97 | 1.01 |
| Price-to-Free Cash Flow Ratio (TTM) | 21.47 | 10.08 |